<DOC>
	<DOC>NCT01153906</DOC>
	<brief_summary>The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.</brief_summary>
	<brief_title>Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Both cohorts: Have complete medical insurance coverage and pharmacy benefits. Enrolled female health plan members for at least one year prior to study entry. Age between 9 and 25 years at study entry. Exposed cohort: • Subjects who have received at least one dose of Cervarix®, with or without any other US ageappropriate recommended vaccines. Unexposed cohort: • No further specific inclusion criteria Both cohorts: • Subjects with a diagnostic code of any of the AID endpoints of interest during the one year prior to the index date. Exposed cohort: • Subjects who received any dose of Gardasil® prior to the first dose of Cervarix®. Unexposed cohort: • Subjects who receive any dose of Cervarix® prior to the index date.</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>autoimmune diseases</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>papillomavirus</keyword>
	<keyword>human papillomavirus</keyword>
	<keyword>HPV</keyword>
</DOC>